David Malcom Rodman - 17 Mar 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
17 Mar 2026
Net transactions value
-$10,696
Form type
4
Filing time
17 Mar 2026, 16:51:17 UTC
Previous filing
16 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rodman David Malcom Chief Medical Officer 150 N. RADNOR CHESTER RD., SUITE F200, RADNOR /s/ Adam Levy, Attorney-in-fact 17 Mar 2026 0001672659

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Options Exercise +417 +0.55% $15.44* 76,557 17 Mar 2026 Direct F1
transaction MLYS Common Stock Sale $10,696 -417 -0.54% $25.65 76,140 17 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Options Exercise -417 -7.7% $0.000000* 5,000 17 Mar 2026 Common Stock 417 $15.44 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
F2 The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.